PRESCRIPTION OF IMMUNOGLOBULIN REPLACEMENT THERAPY FOR PATIENTS WITH NON-CLASSICAL AND SECONDARY ANTIBODY DEFICIENCY: AN ANALYSIS OF PRACTICE IN THE UNITED KINGDOM & REPUBLIC OF IRELAND.

Author(s):  
Edgar John David
2017 ◽  
Vol 52 ◽  
pp. 136-142 ◽  
Author(s):  
Antonio Pecoraro ◽  
Ludovica Crescenzi ◽  
Francescopaolo Granata ◽  
Arturo Genovese ◽  
Giuseppe Spadaro

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0223861
Author(s):  
Tri Dinh ◽  
Jun Oh ◽  
Donald William Cameron ◽  
Seung-Hwan Lee ◽  
Juthaporn Cowan

2016 ◽  
Vol 7 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Jarrett E. Walsh ◽  
Jose G. Gurrola ◽  
Scott M. Graham ◽  
Sarah L. Mott ◽  
Zuhair K Ballas

Author(s):  
Bas M. Smits ◽  
Ilona Kleine Budde ◽  
Esther de Vries ◽  
Ineke J. M. ten Berge ◽  
Robbert G. M. Bredius ◽  
...  

Abstract Background Patients with an IgG subclass deficiency (IgSD) ± specific polysaccharide antibody deficiency (SPAD) often present with recurrent infections. Previous retrospective studies have shown that prophylactic antibiotics (PA) and immunoglobulin replacement therapy (IRT) can both be effective in preventing these infections; however, this has not been confirmed in a prospective study. Objective To compare the efficacy of PA and IRT in a randomized crossover trial. Methods A total of 64 patients (55 adults and 9 children) were randomized (2:2) between two treatment arms. Treatment arm A began with 12 months of PA, and treatment arm B began with 12 months of IRT. After a 3-month bridging period with cotrimoxazole, the treatment was switched to 12 months of IRT and PA, respectively. The efficacy (measured by the incidence of infections) and proportion of related adverse events in the two arms were compared. Results The overall efficacy of the two regimens did not differ (p = 0.58, two-sided Wilcoxon signed-rank test). A smaller proportion of patients suffered a related adverse event while using PA (26.8% vs. 60.3%, p < 0.0003, chi-squared test). Patients with persistent infections while using PA suffered fewer infections per year after switching to IRT (2.63 vs. 0.64, p < 0.01). Conclusion We found comparable efficacy of IRT and PA in patients with IgSD ± SPAD. Patients with persistent infections during treatment with PA had less infections after switching to IRT. Clinical Implication Given the costs and associated side-effects of IRT, it should be reserved for patients with persistent infections despite treatment with PA.


Sign in / Sign up

Export Citation Format

Share Document